NCT lookup

Inclusion criteria:

Phase 1:

* For dose escalation cohorts, participants with confirmed selected CD38+ hematological malignancies as specified below who had progressed on after standard therapy or for whom there was no effective standard therapy (refractory/relapsed participants). B-cell Non-Hodgkin-lymphoma/leukemia (NHL) participants with at least 1 measurable lesion. Multiple myeloma (MM) participants with measurable M-protein serum and/or 24-hour urine. Acute myeloid leukemia (AML) participants, all types except M3 based on French-American-British (FAB) classification. Acute Lymphoblastic Leukemia (B-cell ALL) participants. Chronic lymphocytic leukemia (CLL) participants.
* For expansion cohorts, participants with relapsed/refractory MM with measurable M-protein (serum M-protein of \>0.5 g/dL and/or urine M-protein of \>200 mg (24-hr urine)) or elevated serum free light chains (FLC) \>10 mg/dL with abnormal FLC ratio) who had progressed on or after standard therapy that included an Immunomodulatory drug (IMiD) and a proteasome inhibitor and who met the protocol defined criteria for standard risk or high risk.

Phase 2:

* Participants had a known diagnosis of multiple myeloma with evidence of measurable disease, and have evidence of disease progression based on International Myeloma Working Group (IMWG) criteria: Serum M-protein ≥1 g/dL, or urine M-protein \>=200 mg/24 hours or in the absence of measurable m-protein, serum FLC \>=10 mg/dL, and abnormal serum immunoglobulin kappa lambda FLC ratio (\<0.26 or \>1.65).
* Participants who received at least three prior lines of therapy for MM and had treatment with an IMiD (for \>=2 cycles or \>=2 months of treatment) and a proteasome inhibitor (PI) (for \>=2 cycles or \>=2 months of treatment) OR participants whose disease was double refractory to an IMiD and a PI. For participants who had received more than 1 type of IMiD and PI, their disease must be refractory to the most recent one.
* Participants who had achieved a minimal response or better to at least one prior line of therapy.
* Participants who had received an alkylating agent (\>=2 cycles or \>=2 months) either alone or in combination with other MM treatments.
* Stage 2 only: Participants who had evidence of disease progression on or after the most recent prior regimen based on IMWG criteria.

Exclusion criteria:

Phase 1:

* Karnofsky performance status \<60
* Poor bone marrow reserve
* Poor organ function
* Known intolerance to infused protein products, sucrose, histidine, polysorbate 80 or known hypersensitivity to any of the components of the study therapy that was not amenable to pre-medication with steroids and H2 blockers
* Any serious active disease (including clinically significant infection that was chronic, recurrent, or active) or co-morbid condition, which, in the opinion of the investigator, interfered with the safety, the compliance with the study or with the interpretation of the results
* Any severe underlying medical conditions including presence of laboratory abnormalities, which could impair the ability to participate in the study or the interpretation of its results

Phase 2:

* Participants with multiple myeloma immunoglobulin M (IgM) subtype
* Previous treatment with any anti-CD38 therapy
* Participants with concurrent plasma cell leukemia
* Participants with known or suspected amyloidosis
* Karnofsky performance status \<60 (stage 1)/Eastern Cooperative Oncology Group (ECOG) Performance status \>2 (stage 2).
* Poor bone marrow reserve
* Poor organ function
* Known intolerance to infused protein products, sucrose, histidine, polysorbate 80 or known hypersensitivity to any of the components of the study therapy that was not amenable to pre-medication with steroids and H2 blockers
* Any serious active disease (including clinically significant infection that was chronic, recurrent, or active) or co-morbid condition, which, in the opinion of the investigator, interfered with the safety, the compliance with the study or with the interpretation of the results
* Any severe underlying medical conditions including presence of laboratory abnormalities, which impaired the ability to participate in the study or the interpretation of its results

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

• Scottsdale, Arizona, United States
• San Francisco, California, United States
• Atlanta, Georgia, United States
• Chicago, Illinois, United States
• Ann Arbor, Michigan, United States
• Detroit, Michigan, United States
• Rochester, Minnesota, United States
• St Louis, Missouri, United States
• Hackensack, New Jersey, United States
• New York, New York, United States
• Durham, North Carolina, United States
• Cincinnati, Ohio, United States
• Nashville, Tennessee, United States
• Salt Lake City, Utah, United States
• Seattle, Washington, United States
• Milwaukee, Wisconsin, United States
• Capital Federal, Buenos Aires, Argentina
• Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
• Ciudad de Buenos Aires, Buenos Aires, Argentina
• Antwerp, Belgium
• Porto Alegre, Rio Grande do Sul, Brazil
• Barretos, São Paulo, Brazil
• São Paulo, São Paulo, Brazil
• Rio de Janeiro, Brazil
• Temuco, La Araucanía, Chile
• Helsinki, Finland
• Turku, Finland
• Nantes, France
• Pierre-Bénite, France
• Toulouse, France
• + 29 more on CT.gov